4.4 Article

Power doppler ultrasound signal predicts abnormal HDL function in patients with rheumatoid arthritis

Journal

RHEUMATOLOGY INTERNATIONAL
Volume 43, Issue 6, Pages 1041-1053

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s00296-023-05285-7

Keywords

Rheumatoid arthritis; Ultrasound; High-density lipoprotein

Categories

Ask authors/readers for more resources

Active rheumatoid arthritis (RA) is associated with increased cardiovascular risk and impaired function of high-density lipoprotein (HDL). The study evaluated the association between synovial power doppler ultrasound signal (PDUS) and HDL function and structure. Patients with higher baseline PDUS scores had worse HDL function, and treatment with tocilizumab or abatacept led to improvements in HDL function. These findings support previous research suggesting a direct link between joint inflammation and abnormal HDL function.
Active rheumatoid arthritis (RA) is associated with increased cardiovascular risk and impaired function of high-density lipoprotein (HDL). Previous work suggests that HDL may become dysfunctional through oxidative modifications within the RA joint. The current work evaluates an association of synovial power doppler ultrasound signal (PDUS) with HDL function and structure. Two open-label clinical therapeutic studies using PDUS as a disease outcome measure were included in this analysis, including a 12-month trial of subcutaneous abatacept in 24 RA patients and a 6-month trial of IV tocilizumab in 46 RA patients. Laboratory assays included assessments of HDL function and structure, HDL and total cholesterol levels, and a cytokine/chemokine panel. Patients with the highest baseline PDUS scores in both clinical studies, had worse HDL function, including suppression of paraoxonase 1 (PON1) activity as well as lower HDL-C levels. Associations between other disease assessments (DAS28 and CDAI) and HDL function/structure were noted but were generally of lesser magnitude and consistency than PDUS across the HDL profile. Treatment with tocilizumab for 6 months was associated with increases in cholesterol levels and improvements in the HDL function profile, which correlated with greater decreases in PDUS scores. Similar trends were noted following treatment with abatacept for 3 months. Higher baseline PDUS scores identified patients with worse HDL function. This data supports previous work suggesting a direct association of joint inflammation with abnormal HDL function.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available